Jiangsu Nhwa Pharmaceutical Co., LTD (SHE:002262)

Market Cap	23.95B
Revenue (ttm)	5.53B
Net Income (ttm)	1.17B
Shares Out	1.02B
EPS (ttm)	1.16
PE Ratio	20.31
Forward PE	16.57
Dividend	0.32 (1.36%)
Ex-Dividend Date	May 15, 2024

Volume	23,087,947
Average Volume	16,166,262
Open	22.18
Previous Close	23.43
Day's Range	22.18 - 24.09
52-Week Range	20.49 - 29.98
Beta	-0.00
RSI	65.71
Earnings Date	Mar 29, 2025

About SHE:002262

Jiangsu Nhwa Pharmaceutical Co., LTD engages in production, marketing, and services related to central nervous system drugs in China. It’s product portfolio includes Duloxetine Hcl, Risperidone, Ziprasidone Hcl, Etomidate Fat Emulsion, Gabapentin, Zaleplon, etc.; and Iptakalim, an anti-hypertension drug. The company’s products are used for treatment of anesthesiology, psychiatry and neurology, as well as APIs. Jiangsu Nhwa Pharmaceutical Co., LTD was founded in 1978 and is headquartered in Xuzhou, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1978
• Employees: 5,394
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002262

Financial Performance

In 2023, SHE:002262's revenue was 5.04 billion, an increase of 17.28% compared to the previous year's 4.30 billion. Earnings were 1.04 billion, an increase of 15.12%.